Your browser doesn't support javascript.
loading
Alternatives to antibiotics-a pipeline portfolio review.
Czaplewski, Lloyd; Bax, Richard; Clokie, Martha; Dawson, Mike; Fairhead, Heather; Fischetti, Vincent A; Foster, Simon; Gilmore, Brendan F; Hancock, Robert E W; Harper, David; Henderson, Ian R; Hilpert, Kai; Jones, Brian V; Kadioglu, Aras; Knowles, David; Ólafsdóttir, Sigríður; Payne, David; Projan, Steve; Shaunak, Sunil; Silverman, Jared; Thomas, Christopher M; Trust, Trevor J; Warn, Peter; Rex, John H.
Afiliação
  • Czaplewski L; Chemical Biology Ventures, Abingdon, Oxfordshire, UK; Abgentis, Edgbaston, Birmingham, UK; Persica Pharmaceuticals, Canterbury, Kent, UK. Electronic address: lloyd.czaplewski@chembioventures.com.
  • Bax R; Transcrip Partners Reading, Berkshire, UK.
  • Clokie M; Department of Infection, Immunity and Inflammation, University of Leicester, Leicester, UK.
  • Dawson M; Novacta Biosystems, Welwyn Garden City, Hertfordshire, UK; Cantab Anti-infectives, Welwyn Garden City, Hertfordshire, UK.
  • Fairhead H; Phico Therapeutics, Babraham, Cambridge, UK.
  • Fischetti VA; Laboratory of Bacterial Pathogenesis and Immunology, The Rockefeller University, New York, NY, USA.
  • Foster S; Department of Molecular Biology and Biotechnology, University of Sheffield, Sheffield, UK; Absynth Biologics, Liverpool, UK.
  • Gilmore BF; School of Pharmacy, Queen's University, Belfast, UK.
  • Hancock RE; Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
  • Harper D; Evolution Biotechnologies, Ampthill, Bedfordshire, UK.
  • Henderson IR; Institute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham, UK.
  • Hilpert K; Institute of Infection and Immunity, St George's, University of London, London, UK; TiKa Diagnostics, London, UK.
  • Jones BV; School of Pharmacy and Biomolecular Sciences, University of Brighton, Brighton, UK; Queen Victoria Hospital NHS Foundation Trust, East Grinstead, West Sussex, UK.
  • Kadioglu A; Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.
  • Knowles D; Absynth Biologics, Liverpool, UK; Procarta Biosystems, Norwich, UK.
  • Ólafsdóttir S; Icelandic Medicines Agency, Reykjavik, Iceland.
  • Payne D; GlaxoSmithKline, Collegeville, Pennsylvania, PA, USA.
  • Projan S; MedImmune, Gaithersburg, MD, USA.
  • Shaunak S; Department of Medicine, Imperial College London, London, UK.
  • Silverman J; Kaleido Biosciences, Cambridge, MA, USA.
  • Thomas CM; Institute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham, UK; Plasgene, Edgbaston, Birmingham, UK.
  • Trust TJ; Pan-Provincial Vaccine Enterprise, Saskatoon, SK, Canada.
  • Warn P; Evotec, Manchester, UK.
  • Rex JH; AstraZeneca, Boston, MA, USA; F2G, Manchester, UK.
Lancet Infect Dis ; 16(2): 239-51, 2016 Feb.
Article em En | MEDLINE | ID: mdl-26795692
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bactérias / Infecções Bacterianas / Vacinas / Drogas em Investigação / Farmacorresistência Bacteriana / Antibacterianos Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Bactérias / Infecções Bacterianas / Vacinas / Drogas em Investigação / Farmacorresistência Bacteriana / Antibacterianos Limite: Humans Idioma: En Revista: Lancet Infect Dis Ano de publicação: 2016 Tipo de documento: Article